OptiBiotix Health (OB3) AI Stock Analysis

0 Followers

OptiBiotix Health

(Frankfurt:OB3)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue GrowthThe sharp increase in 2025 revenue indicates stronger commercial traction for the company’s probiotic and microbiome products. If partner-led launches and customer demand continue, this growth can provide greater operating leverage and support broader market penetration over the next several quarters.

Negative Factors

Persistent and Widening LossesContinuing losses show that revenue growth has not yet translated into a viable earnings model. With operating costs still scaling faster than revenue, the company may need sustained growth or further cost discipline before its commercial progress produces durable profitability.

OptiBiotix Health (OB3) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.78M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -1.3
Beta (1Y): 0.81
Revenue Growth: 8.23%
EPS Growth: -2881.25%
Country: Germany
Employees: 9
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

OptiBiotix Health Business Overview & Revenue Model

Company Description

OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and...

OptiBiotix Health Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:OB3 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:SBTX	59Neutral	GBP 13.61M	-27.78	-5.25%	―	95.16%	85.60%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:FUM	42Neutral	GBP 2.82M	-0.30	-152.41%	―	-70.77%	60.39%
GB:TCF	42Neutral	GBP 4.64M	-1.70	-93.92%	―	―	55.56%
GB:CIZ	39Underperform	GBP 5.52M	-7.19	192.61%	―	―	42.86%
GB:NFX	39Underperform	GBP 2.61M	-2.12	-83.53%	―	―	93.02%

* Healthcare Sector Average

Performance Comparison

DE:OB3 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:OB3	OptiBiotix Health	0.06	-0.02	-23.81%
GB:TCF	Evgen Pharma	0.17	-0.04	-19.05%
GB:FUM	Futura Medical	0.19	-2.04	-91.52%
GB:NFX	Nuformix Plc	0.10	-0.27	-72.60%
GB:CIZ	Cizzle Biotechnology Holdings PLC	1.15	-0.60	-34.29%
GB:SBTX	SkinBioTherapeutics plc	5.00	-10.50	-67.74%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

OptiBiotix Health AI Stock Analysis